Cyprotex Discovery Receives French Research Tax Credit Accreditation

News provided by

Cyprotex

Apr 21, 2010, 03:06 ET

MACCLESFIELD, England, April 21, 2010 /PRNewswire/ -- Cyprotex (AIM:CRX), the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.

The French Ministry of Research (Ministere de l'Enseignement Superieur et de la Recherche) has granted the French R&D tax credit ("Credit d'Impot Recherche", CIR) accreditation to Cyprotex as of March 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in R&D requirements that are outsourced to Cyprotex Discovery.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are delighted to receive this recognition and approval from the French Ministry of Research which will provide greater opportunities to support our current client base and allow for improved collaborations with future French clients.'

Additional information on the French research tax credit system is available from the Ministere de l'Enseignement Superieur et de la Recherche site - http://www.enseignementsup-recherche.gouv.fr/

    For further information:

    Cyprotex PLC
    Dr. Anthony Baxter, Chief Executive Officer
    Tel: +44-1625-505-100
    [email protected]
    http://www.cyprotex.com

    Execution Noble & Company Limited
    John Llewellyn-Lloyd
    Sam Reynolds
    Tel: +44(0)20-7456-9191

    Public Relations
    Financial Dynamics
    Ben Brewerton
    Ben Atwell
    Mo Noonan
    Tel: +44(0)20-7831-3113

SOURCE Cyprotex

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED